Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C4-dietary oil (1,3-dibutyryl-2-oleoylglycerol) is a synthetic structured triacylglycerol designed to stimulate the release of incretin hormones while providing fewer calories than conventional dietary fats. It is composed of an oleic acid moiety at the sn-2 position and butyric acid at the sn-1 and sn-3 positions. Upon ingestion and subsequent digestion by gastric and pancreatic lipases, the butyric acid is cleaved, releasing 2-oleoylglycerol (2-OG). 2-OG acts as a potent agonist for the G protein-coupled receptor 119 (GPR119) located on intestinal L-cells and K-cells, triggering the secretion of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This mechanism enhances postprandial incretin responses, which can improve glucose metabolism and insulin secretion. It has been investigated as a potential dietary intervention for managing overweight individuals with type 2 diabetes and obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1,3-dibutyryl-2-oleoylglycerol.